Why is the ₹2.25 crore investment important for Crestchem?

The investment represents about 6% of the company's total market value. For a nano-cap, committing that share of equity to a new venture is a material decision.

How did the core business perform in FY26?

Annual revenue increased 18% to ₹29.61 crore from ₹25.07 crore the prior year. Net profit for the full year was ₹2.71 crore, roughly in line with the prior period.

What dividend did the board recommend?

The board recommended a final dividend of ₹1.50 per equity share, which is a 15% payout on the face value of the shares.

Who will lead the company through this expansion?

The board reappointed Managing Director Dipak Patel and other long-standing executives to new five-year terms starting in late 2026.

Earnings · Chemicals · Micro cap

Crestchem puts ₹2.25 cr behind its oleochem subsidiary

The nano-cap is funding Oleo Biosciences with a commitment equal to 6% of its market value. FY26 revenue grew 18%.

CRSTCHM By Tipsheet Editorial 29 May 2026 · 5:38 PM IST Verify on BSE · NSE

Mkt cap₹37.2 cr

P/E16.76×

ROE36.47%

Debt / eq.0.00

Div yld0.81%

₹2.25 cr Capital commitment to new subsidiary Oleo Biosciences

What's new

Board approved a ₹2.25 crore investment in new subsidiary Oleo Biosciences.
FY26 revenue grew 18% to ₹29.61 crore; net profit held at ₹2.71 crore.
Recommended a ₹1.50 per share final dividend (15% on face value).

Why this matters

For a company of this size, a ₹2.25 crore bet on a new subsidiary is not trivial. It turns a strategic idea into a funded, active project.

What we're watching

First financial or operational updates from Oleo Biosciences.
Whether Crestchem needs to raise further funds for the subsidiary.
How the new business integrates with existing operations.

The full read

Crestchem's FY26 results are steady. Revenue rose 18% to ₹29.61 crore. Net profit held at ₹2.71 crore. The board is paying a ₹1.50 per share dividend. The real news is the ₹2.25 crore commitment to Oleo Biosciences. That equals about 6% of the company's market value. It turns talk of an oleochem pivot into a funded project. Management reappointments for five years lock in the team. The subsidiary now has a balance sheet, not just a board resolution. A small company making a big bet.

Questions answered

Why is the ₹2.25 crore investment important for Crestchem?: The investment represents about 6% of the company's total market value. For a nano-cap, committing that share of equity to a new venture is a material decision.
How did the core business perform in FY26?: Annual revenue increased 18% to ₹29.61 crore from ₹25.07 crore the prior year. Net profit for the full year was ₹2.71 crore, roughly in line with the prior period.
What dividend did the board recommend?: The board recommended a final dividend of ₹1.50 per equity share, which is a 15% payout on the face value of the shares.
Who will lead the company through this expansion?: The board reappointed Managing Director Dipak Patel and other long-standing executives to new five-year terms starting in late 2026.

Mentioned: Oleo Biosciences Private Limited · ₹2.25 cr investment · Dipak Patel

Primary source BSE · NSE

An independent reading of the company's own disclosure — the primary filing above is the final word.